Trade with Eva: Analytics in action >>
Showing posts with label KURA. Show all posts
Showing posts with label KURA. Show all posts

Friday, September 8, 2017

=Kura Oncology (KURA): positive mid-stage trial results

  • Stock: KURA (NASDAQ) 
  • Headquarters: La Jolla, CA
  • CEO: Troy Wilson
  • Founded: 2007
  • kuraoncology.com



Kura Oncology announces its Phase 2 trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck met its primary endpoint
  • The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment.
  • Four confirmed, partial responses and two patients with disease stabilization have been observed among the first six evaluable HNSCC patients enrolled in the trial.
  • In addition, objective responses greater than one year in duration have already been observed in two patients.
****

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-53.27%-35.09%
Return on average equity-66.82%-39.66%
Employees30